{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 31,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "RP2D: Recommended Phase 2 Dose",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/6",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Platinum-resistant ovarian cancer: Collaboration with MSD for phase 3; finalizing plans for phase 3 combination study with KEYTRUDA.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f5660f1-d7a5-4f6e-88b6-55d65ac60f9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Rapid progress in clinical development program enrollment: 221 patients recruited; ARTISTRY-1 enrollment complete; ARTISTRY-2 dose escalation complete.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fd928de-c94b-4406-a737-bffa707f39c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Mucosal melanoma: Orphan Drug Designation granted; ARTISTRY-6 phase 2 study initiated.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "613d53b3-8b4f-4e92-8659-f8f95734b6e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "RP2D: Recommended Phase 2 Dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cfc08f4-8bc2-401a-bd62-042ed5179692",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Nemvaleukin Alfa Development Program Progress",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e39065f4-e9f9-4078-9876-040867983bc5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "9d10978f-3990-4d84-8bb4-62cb736a5066",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The presentation highlights the need for new treatments for certain types of cancer",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "38371bff-6368-45c8-9640-033e6721da71",
      "evidence": "The presentation highlights the need for new treatments",
      "position": 1,
      "objective": "What are the consequences of not having effective treatments for certain types of cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}